VOR Stock Forecast 2025-2026
Distance to VOR Price Targets
VOR Price Momentum
10 Quality Stocks Worth Considering Now
Researching Vor Biopharma (VOR) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on VOR and similar high-potential opportunities.
Latest VOR Stock Price Targets & Analyst Predictions
Based on our analysis of 9 Wall Street analysts, VOR has a bullish consensus with a median price target of $8.00 (ranging from $5.00 to $18.00). The overall analyst rating is Strong Buy (9.4/10). Currently trading at $0.85, the median forecast implies a 844.2% upside. This outlook is supported by 7 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Justin Walsh at JonesTrading, projecting a 2,024.4% upside. Conversely, the most conservative target is provided by Stephen Willey at Stifel, suggesting a 490.1% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
VOR Analyst Ratings
VOR Price Target Range
Latest VOR Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for VOR.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 21, 2025 | Oppenheimer | Matthew Biegler | Outperform | Reiterates | $8.00 |
| Mar 21, 2025 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Maintains | $13.00 |
| Mar 21, 2025 | Stifel | Stephen Willey | Buy | Maintains | $5.00 |
| Dec 10, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $17.50 |
| Dec 10, 2024 | JMP Securities | Silvan Tuerkcan | Market Outperform | Reiterates | $12.00 |
| Nov 8, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $17.50 |
| Nov 8, 2024 | Baird | Jack Allen | Outperform | Maintains | $14.00 |
| Sep 6, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $17.50 |
| Sep 6, 2024 | JMP Securities | Silvan Tuerkcan | Market Outperform | Reiterates | $12.00 |
| Aug 14, 2024 | Barclays | Carter Gould | Overweight | Maintains | $3.00 |
| May 13, 2024 | JMP Securities | Silvan Tuerkcan | Market Outperform | Reiterates | $12.00 |
| May 13, 2024 | Oppenheimer | Matthew Biegler | Outperform | Reiterates | $10.00 |
| May 10, 2024 | Wedbush | David Nierengarten | Outperform | Reiterates | $11.00 |
| Apr 23, 2024 | Wedbush | David Nierengarten | Outperform | Reiterates | $11.00 |
| Mar 22, 2024 | JMP Securities | Silvan Tuerkcan | Market Outperform | Reiterates | $12.00 |
| Mar 21, 2024 | Wedbush | David Nierengarten | Outperform | Reiterates | $11.00 |
| Mar 21, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $17.50 |
| Mar 21, 2024 | Stifel | Stephen Willey | Buy | Maintains | $12.00 |
| Mar 21, 2024 | Oppenheimer | Matthew Biegler | Outperform | Reiterates | $15.00 |
| Jan 18, 2024 | Wedbush | David Nierengarten | Outperform | Reiterates | $11.00 |
Vor Biopharma Inc. (VOR) Competitors
The following stocks are similar to Vor Biopharma based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Vor Biopharma Inc. (VOR) Financial Data
Vor Biopharma Inc. has a market capitalization of $110.42M with a P/E ratio of 0.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -94.5%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Vor Biopharma Inc. (VOR) Business Model
About Vor Biopharma Inc.
Develops innovative treatments for blood cancers.
Vor Biopharma operates as a clinical-stage biopharmaceutical company focused on creating engineered hematopoietic stem cells (eHSCs) that enhance treatment outcomes for hematological malignancies. By leveraging a proprietary platform, the company aims to improve graft compatibility and efficacy, allowing for more targeted therapies that minimize the adverse effects of traditional treatments.
The company is positioned at the forefront of genetic engineering and targeted therapeutics within the biotech industry. With ongoing research and clinical trials, Vor Biopharma aspires to pioneer advancements in cancer treatment and personalized medicine, which may significantly impact future developments in the biopharmaceutical sector.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
168
CEO
Dr. Robert Ang M.B.A., M.D., MBBS
Country
United States
IPO Year
2001
Website
www.vorbio.comVor Biopharma Inc. (VOR) Latest News & Analysis
Vor Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update
6 days agoVor Bio (Nasdaq: VOR) plans to update clinical data for VCAR33 in H1 2025 and for trem-cel + Mylotarg in H2 2025. A $55.6 million private placement was completed in December 2024.
Upcoming clinical data updates and trial initiations for Vor Bio signal potential advancements in their therapies, influencing investor sentiment on growth prospects and future valuation.
Vor Bio presented research highlighting that clinical trial complexity and logistical challenges delay enrollment in cell and gene therapy trials, despite continued patient interest in these treatments.
Delays in cell and gene therapy trial enrollment due to logistical challenges can impact company timelines and potential revenue, influencing investor sentiment and stock performance.
Vor Bio to Participate in the Oppenheimer's 35th Annual Healthcare Life Sciences Conference
1 month agoVor Bio (Nasdaq: VOR) will participate in a fireside chat and host virtual 1x1 investor meetings at Oppenheimer's 35th Annual Healthcare Life Sciences Conference.
Vor Bio's participation in a prominent healthcare conference may increase visibility, attract investor interest, and potentially influence stock performance through strategic discussions.
Vor Biopharma Inc. (VOR) has reached a key support level, with its 50-day moving average recently crossing above the 200-day moving average, indicating a potential positive trend.
Vor Biopharma's technical indicators suggest potential upward momentum, with a key support level and a "golden cross" signaling bullish trends, attracting investor interest.
Vor Bio Appoints Life Sciences and Technology Investor and Entrepreneur, Mr. Erez Kalir to its Board of Directors
2 months agoVor Bio (Nasdaq: VOR) appointed Erez Kalir to its Board of Directors, adding a seat following a PIPE financing led by Reid Hoffman, where Kalir represents Reprogrammed Interchange, LLC.
Erez Kalir's appointment to Vor Bio's Board indicates strategic backing from Reid Hoffman, potentially enhancing governance and attracting further investment, impacting stock performance.
Vor Bio Announces $55.6 Million Private Placement
2 months agoUpdated clinical data for the VBP301 trial of VCAR33 ALLO is expected in H1 2025, and for the VBP101 trial of trem-cel with Mylotarg in H2 2025.
Upcoming clinical data releases can significantly impact stock prices, influencing investor sentiment and potential market value for the involved companies.
Frequently Asked Questions About VOR Stock
What is Vor Biopharma Inc.'s (VOR) stock forecast for 2025?
Based on our analysis of 9 Wall Street analysts, Vor Biopharma Inc. (VOR) has a median price target of $8.00. The highest price target is $18.00 and the lowest is $5.00.
Is VOR stock a good investment in 2025?
According to current analyst ratings, VOR has 7 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.85. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for VOR stock?
Wall Street analysts predict VOR stock could reach $8.00 in the next 12 months. This represents a 844.2% increase from the current price of $0.85. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Vor Biopharma Inc.'s business model?
Vor Biopharma operates as a clinical-stage biopharmaceutical company focused on creating engineered hematopoietic stem cells (eHSCs) that enhance treatment outcomes for hematological malignancies. By leveraging a proprietary platform, the company aims to improve graft compatibility and efficacy, allowing for more targeted therapies that minimize the adverse effects of traditional treatments.
What is the highest forecasted price for VOR Vor Biopharma Inc.?
The highest price target for VOR is $18.00 from Justin Walsh at JonesTrading, which represents a 2,024.4% increase from the current price of $0.85.
What is the lowest forecasted price for VOR Vor Biopharma Inc.?
The lowest price target for VOR is $5.00 from Stephen Willey at Stifel, which represents a 490.1% increase from the current price of $0.85.
What is the overall VOR consensus from analysts for Vor Biopharma Inc.?
The overall analyst consensus for VOR is bullish. Out of 9 Wall Street analysts, 7 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $8.00.
How accurate are VOR stock price projections?
Stock price projections, including those for Vor Biopharma Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
